Researchers identified Janus kinase inhibitors as a promising treatment for the severe drug-induced skin condition toxic epidermal necrolysis, by analyzing patient biopsies with deep visual proteomics.
Coherus and Junshi’s PD-1 inhibitor approved for nasopharyngeal carcinoma – Pharmaceutical Technology
Coherus licensed Loqtorzi from Junshi for marketing in the US and Canada in February 2021. Image Credit: Prostock-studio / Shutterstock. The US Food and Drug
October 30, 2023